Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2022MoleculesOpen Access

Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiaopeng HuYangtze UniversityXWXisheng WangTongji UniversityXXXingkui XueLonggang Central Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hu et al. (2022) studied this question.

synapsesocial.com/papers/69d900b749e640f9cad18006https://doi.org/10.3390/molecules27144498
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system2016 · 441 citations
  2. 2CD26/dipeptidylpeptidase IV—chemokine interactions: double-edged regulation of inflammation and tumor biology2016 · 107 citations
  3. 3The structure and function of CD26 in the T‐cell immune response1998 · 426 citations
  4. 4Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes2013 · 2,538 citations
  5. 5Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis2021 · 14 citations